• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SNDL Reports Third Quarter 2023 Financial and Operational Results and Achieves Positive Net Cash from Operating Activities and Free Cash Flow

    11/13/23 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email

    CALGARY, AB, Nov. 13, 2023 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the third quarter ended September 30, 2023. Unless otherwise indicated, all financial information in this press release is reported in millions of Canadian dollars.

    SNDL Inc. logo (CNW Group/SNDL Inc.)

    SNDL has also posted a supplemental investor presentation on its website, at https://sndl.com.

    THIRD QUARTER 2023 FINANCIAL AND OPERATIONAL HIGHLIGHTS

    • Net cash provided by operating activities of $27.5 million in the third quarter of 2023, compared to $8.6 million in the third quarter of 2022.
    • Positive free cash flow1 of $16.5 million in the third quarter of 2023, compared to negative $67.1 million in the third quarter of 2022.
    • As of September 30, 2023, SNDL's unrestricted cash stood at $202.0 million, up from $185.5 million on June 30, 2023. This 8.9% sequential increase can be attributed to effective cash-generating initiatives and operational efficiencies implemented throughout the quarter, particularly in working capital. 
    • Net revenue for the third quarter of 2023 of $237.6 million, compared to $230.5 million in the third quarter of 2022, an increase of 3.1%.
      • Liquor Retail: Net revenue of $151.8 million for the third quarter of 2023, showing stable revenue compared to the same quarter in the prior year.
      • Cannabis Retail: Net revenue of $75.5 million for the third quarter of 2023, an increase of 14.1% compared to the same quarter of the prior year.
      • Cannabis Operations: Net revenue of $21.0 million for the third quarter of 2023, an increase of 77.4% compared to the same quarter of the prior year.
    • Gross margin of $48.6 million in the third quarter of 2023, compared to $50.3 million in the third quarter of 2022, a 3.4% decrease driven by non-cash inventory impairments.
    • Net loss of $21.8 million for the third quarter of 2023, compared to a loss of $98.8 million in the third quarter of 2022, an improvement of 77.9% mainly driven by asset impairments recorded in 2022.
    • Adjusted EBITDA of $16.1 million for the third quarter of 2023, compared to $18.3 million from the third quarter of 2022.
    • SNDL currently has five credit investments in the SunStream portfolio following the monetization of one credit exposure in the third quarter of 2023.  

    _____________________________

    1 See Specified Financial Measures – Free Cash Flow

    "SNDL's positive net cash from operating activities and first quarter of free cash flow generation marks a pivotal milestone, reflecting our team's commitment to operational and financial excellence," said Zach George, Chief Executive Officer of SNDL. "We are intent on realizing SNDL's potential for improved profitability, material growth and greater efficiencies across all of our segments. We recently commenced our Liquor Retail data program and continue to see margin improvements in our Cannabis Retail network. In addition, we have rationalized our facility footprint and are moving aggressively into procurement to drive improved results in our Cannabis Operations segment. As previously disclosed, we are in the advanced stages of restructuring key U.S. credit exposures in a manner compliant with U.S. laws. Our commitment to delight consumers remains steadfast as we work to deliver cost-effective, high-quality products and exceptional retail experiences. While we have made significant progress and recognize our achievements, our goals are a far climb from where we stand today. Our industry-leading balance sheet and improved operations enable us to avoid short-term thinking in order to build the foundations of a business that we believe will create sustainable shareholder value through strong free cash flow generation." 

    THIRD QUARTER 2023 KEY FINANCIAL METRICS

    OPERATING SEGMENTS





































    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Three months ended September 30, 2023     





































    Net revenue



    151,801





    75,539





    20,954





    —





    (10,699)





    237,595



    Gross margin



    37,263





    20,046





    (8,704)





    —





    —





    48,605



    Income (loss) from operations



    8,257





    3,481





    (13,971)





    9,886





    (24,023)





    (16,370)









































    Three months ended September 30, 2022





































    Net revenue



    152,488





    66,202





    11,810





    —





    —





    230,500



    Gross margin



    35,568





    14,494





    247





    —





    —





    50,309



    Income (loss) from operations



    13,302





    (83,708)





    (5,673)





    7,936





    (20,399)





    (88,542)



    THIRD QUARTER 2023 RESULTS

    SNDL's business is operated and reported in four segments: Liquor Retail, Cannabis Retail, Cannabis Operations and Investments. 

    Liquor Retail

    SNDL is Canada's largest private sector liquor retailer, operating 170 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond", "Liquor Depot" and "Ace Liquor".

    • Net revenue for Liquor Retail sales for the three banners combined was $151.8 million for the third quarter of 2023, showcasing stable revenue compared to $152.5 million in the same quarter in the prior year.
    • For locations operational throughout the third quarter of 2023 and 2022, same-store sales remained stable year-over-year across all liquor banners.
    • Gross margin in the Liquor Retail segment was $37.3 million, or 24.5% of sales in the third quarter of 2023, compared to $35.6 million, or 23.3% of sales, in the third quarter of 2022. Gross margin growth added $1.7 million to cash flow, mainly driven by procurement productivity and product mix management initiatives.
    • SNDL launched an e-commerce platform for its Liquor Retail banner Wine and Beyond to drive accretive revenues and meaningful basket growth opportunities. Early observations suggest an average increase in total basket spend for online purchases compared to in-store purchases in the first four weeks post-launch.
    • SNDL has constructed and shared the Liquor Retail proprietary data licensing program framework with its partners. It anticipates revenue generation starting in the first quarter of 2024, helping to further enhance the segment's profit margins.
    • Private label sales, a substantial driver of gross margin growth, increased by 33% compared to the third quarter of 2022 and 7% compared to the second quarter of 2023. This increase is driven by further additions to the private label offerings, particularly within the value segment.
    • The Company expects to launch its first wine private label in the first half of 2024, enhancing its successful private label lineup. This new offering will feature an array of wine varietals sourced from distinguished regions and notable winemakers, all priced attractively, which is expected to contribute to SNDL's margin growth while further distinguishing its liquor retail banners.
    • The Company plans to open a new Wine and Beyond location in Airdrie, Alberta, in the first quarter of 2024 to further drive revenue growth under the banner.
    • As of November 13, 2023, the Ace Liquor store count is 138, the Liquor Depot store count is 20, and the Wine and Beyond store count is 12.

    Cannabis Retail

    With its ownership interest in Nova Cannabis Inc. ("Nova"), SNDL is Canada's largest private-sector cannabis retailer, operating 186 locations under its four retail banners: "Value Buds", "Spiritleaf", "Superette", and "Firesale Cannabis". SNDL's Cannabis Retail strategy is based on several pillars, including the quality of its store locations, its range of products, and the unique experiences it provides customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

    • Net revenue from the Cannabis Retail segment for the third quarter of 2023 was $75.5 million, compared to $66.2 million in the third quarter of 2022, a 14.1% increase year-over-year and a record for the segment since SNDL diversified into Cannabis Retail in 2021.
    • For locations operational throughout the third quarter of 2023 and 2022, same-store sales increased 3.9% year-over-year across all Cannabis Retail banners.
    • Gross margin of $20.0 million, or 26.5% of sales, up from 21.9% of sales in the third quarter of 2022, and a 12.4% increase sequentially showcasing the Company's efforts in continued margin expansion initiatives and data program enhancements.
    • Nova's proprietary data licensing program resulted in revenue for the third quarter of 2023 of $4.0 million, compared to $1.4 million in the third quarter of 2022, representing a 53.8% growth compared to the second quarter of 2023.
    • The Company expanded its collaboration with Nova for Value Buds' private label products. This past quarter, Nova introduced a new 1.2-gram vape to its existing large format flower offerings. From the launch of this product on September 8, 2023, to September 30, 2023, 'Hello My Name is Strawberry' was the bestselling 1.2-gram vape cartridge in Alberta Value Buds stores. The Company anticipates expanding to a full suite of products, with a keen focus on launching pre-rolls in the near future.
    • As of November 13, 2023, the Spiritleaf store count is 87 (22 corporate stores and 65 franchise stores), the Value Buds store count is 92 corporate stores, the Superette store count is five corporate stores, and the Firesale store count is two corporate stores.

    Cannabis Operations

    SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy.

    • Net revenue from the Cannabis Operations segment for the third quarter of 2023 was $21.0 million, a 77.4% increase compared to the third quarter of 2022.
    • Gross margin of negative $8.7 million in the third quarter of 2023, compared to $0.2 million in the third quarter of 2022, mainly due to inventory impairment.
    • SNDL recently announced an additional step towards optimizing its facility footprint to bolster competitiveness and profitability in its Cannabis Operations segment. The Company will consolidate cultivation activities at its Atholville, New Brunswick facility while centralizing manufacturing, processing, and production operations in Kelowna, British Columbia.
    • The Company has implemented innovative strategies in its Atholville, New Brunswick facility to improve cultivation, resulting in an average annual yield of 105 grams per square foot and an average THC potency result of 25%.
    • In the third quarter of 2023, SNDL optimized its brand portfolio rationalizing by close to 50% its total offerings across all brands to focus on high-performing SKUs, key consumer categories and new innovations. This rationalization initiative prioritizes revenue generation and key volume SKUs to deliver increased margins within the Cannabis Operations segment and owned retail locations through 2024.
    • The Company launched 41 SKUs in the third quarter of 2023, primarily focusing on large format flower, vapes, and pre-rolls under its value-driven brands, Palmetto and Versus, aligning with its consumer-driven innovation strategy and retail trends.
    • SNDL worked cross-functionally to roll out the Ontario Cannabis Store flow-through fulfillment process and has since ranked as the #4 licensed producer in dollar sales since the process was implemented.

    Investments

    • As of the end of the third quarter of 2023, the Company had deployed capital into cannabis-related credit investments with a carrying value of $583.2 million, including $550.5 million through the SunStream Bancorp Inc. joint venture ("SunStream").
    • SunStream is a joint venture sponsored by SNDL. SunStream directed the formation of the SunStream USA group of companies ("SunStream USA"), in connection with the restructuring of certain loans controlled by SunStream. SunStream USA is anticipated to be a U.S. platform with one or more independent third-party investors, which will be independently managed and governed. The SunStream USA structure is anticipated to be reviewed by the Nasdaq, as the relevant listing authority for SNDL.
    • For the third quarter of 2023, the investment portfolio generated revenue of $10.0 million, mainly driven by interest and fee revenue of $3.3 million and an increase in the estimated fair value of the Company's U.S. credit investments of $6.6 million.
    • At the end of the third quarter of 2023, the credit portfolio controlled by SunStream comprised five investments: Jushi Holdings Inc., SKYMINT Brands ("Skymint"), Ascend Wellness Holdings, Surterra Holdings, Inc. d/b/a Parallel ("Parallel"), and Columbia Care Inc.
    • On September 22, 2023, an affiliate of SunStream entered into restructuring arrangements relating to investments in Parallel, which contemplate the foreclosure, to a SunStream USA entity, of certain Parallel cannabis operations in Florida, Massachusetts, Texas, and Nevada (the "Parallel Transaction").
    • On October 23, 2023, an affiliate of SunStream announced a receivership court order granting the sale of certain assets of Skymint to a SunStream USA entity (the "Skymint Transaction").
    • The Parallel Transaction and Skymint Transaction are anticipated to close by the end of the first quarter of 2024 and are subject to certain conditions and regulatory approvals.


    Three months ended

    September 30



    Nine months ended

    September 30



    ($000s)

    2023



    2022



    2023



    2022



    Interest and fee revenue

























    Interest revenue from investments at amortized cost



    891





    924





    2,819





    2,737



    Interest and fee revenue from investments at Fair Value

    Through Profit or Loss



    250





    1,095





    1,124





    3,754



    Interest revenue from cash



    2,185





    2,293





    6,780





    4,259







    3,326





    4,312





    10,723





    10,750



    Investment revenue (loss)

























    Realized (losses) gains



    (46,082)





    —





    (138,874)





    389



    Unrealized gains (losses)



    46,167





    (5,513)





    130,267





    (58,685)







    85





    (5,513)





    (8,607)





    (58,296)



    Revenue from direct investments



    3,411





    (1,201)





    2,116





    (47,546)



    Share of profit (loss) of equity-accounted investees                                                 



    6,581





    9,176





    15,161





    (24,711)



    Total investment activities



    9,992





    7,975





    17,277





    (72,257)



    Equity Position

    • $785 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees and no outstanding debt at September 30, 2023, resulting in a net book value of $1.3 billion.
    • The Company's share repurchase program continues to be available to lower the outstanding share float. SNDL will continue to assess opportunities to utilize the program to the extent that management believes it is in the best interest of SNDL's shareholders. For the three months ended September 30, 2023, the Company did not purchase common shares for cancellation. The share repurchase program was set to expire on November 20, 2023, but on November 10, 2023, SNDL's board of directors approved an extension to November 20, 2024.

    STRATEGIC AND ORGANIZATIONAL UPDATE

    SNDL remains focused on building long-term shareholder value through vertical integration, the accretive deployment of cash resources, expansion of its retail distribution network, the further streamlining of the Company's operating structure, and enhanced offerings of high-quality brands within the Liquor Retail, Cannabis Retail and Cannabis Operations segments.

    Integration Initiatives

    Since the acquisition of The Valens Company Inc. in January 2023 (the "Valens Acquisition"), the Company has realized $21.9 million in annualized cost savings, substantially exceeding its total initial target of $10 million. In 2023 alone, SNDL achieved cost savings of $17.8 million at an expenditure of $3.6 million. Most cost savings have been realized through SG&A, supply chain consolidation and operational efficiency. By 2024, run-rate synergies are expected to exceed $40 million annually, and proceeds from asset sales are expected to total $9 million.

    SNDL made significant optimizations to its facility footprint to enhance the competitiveness and profitability of its Cannabis Operations segment. As a result of this key integration initiative, SNDL expects optimizing its facility footprint to result in an additional $10 million in annual savings from its Cannabis Operations segment through reduced fixed overhead, power costs, and increased labour efficiencies.  

    As part of SNDL's commitment to effectively address market demand, the Company is in the process of rationalizing its SKU portfolio. By focusing on high-margin products and continuing to drive innovation, the Company expects to see better margins for the Cannabis Operations segment and through owned retail in the upcoming quarters. This approach is designed to allow the Company to optimize its resources and achieve its long-term goals while maintaining a competitive edge in the market.

    The Company's integration initiatives are critical to SNDL's vision of establishing Canada's largest regulated products platform and generating sustainable free cash flow.

    This press release is intended to be read in conjunction with the Company's condensed consolidated interim Financial Statements and Notes for the three and nine month ended September 30, 2023, and the accompanying Management's Discussion and Analysis ("MD&A"). These reports are available under the Company's profile on SEDAR at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml.

    CONFERENCE CALL  

    The Company will hold a conference call and webcast at 10:30 a.m. EST (8:30 a.m. MST) on Monday, November 13, 2023.

    WEBCAST ACCESS

    To access the live webcast of the call, please visit the following link:

    https://services.choruscall.ca/links/sndl2023q3.html

    REPLAY

    A telephone replay will be available for one month. To access the replay, dial:

    Canada/USA Toll Free: 1-800-319-6413 or International Toll: +1-604-638-9010

    When prompted, enter Replay Access Code: 0541#

    The webcast archive will be available for three months via the link provided above.

    ABOUT SNDL INC. 

    SNDL is a public company whose shares are traded on the Nasdaq under the symbol "SNDL."

    SNDL is the largest private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Firesale Cannabis. SNDL is a licensed cannabis producer and one of the largest vertically integrated cannabis companies in Canada specializing in low-cost biomass sourcing, premium indoor cultivation, product innovation, low-cost manufacturing facilities, and a cannabis brand portfolio that includes Top Leaf, Contraband, Citizen Stash, Sundial Cannabis, Palmetto, Bon Jak, Spiritleaf Selects, Versus Cannabis, Value Buds, Vacay, Grasslands and Superette. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information on SNDL, please go to https://sndl.com/. 

    Forward-Looking Information Cautionary Statement   

    This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals, the Company's ability to achieve improved profitability, growth and efficiencies across all segments, or its goal of sustainable, positive gross margin and positive free cash flow, revenue generation from the Liquor Retail proprietary data licensing program, expansion of product offerings (including the expected launch of the Company's wine private label), the impact of rationalization initiatives on revenue and margins within the Cannabis Operations segment and owned retail locations, the expansion and additional cost savings at the Atholville facility, performance of the Company's investments, including through the SunStream joint venture and SunStream USA, the receipt of regulatory and listing authority approvals necessary to implement the proposed SunStream USA investment structure, the ability to realize expected cost savings in relation to the Valens Acquisition, expected run-rate synergies and expected proceeds from future asset sales, and any other potential forms of shareholder value creation.. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "likely", "outlook", "forecast", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Item 3.D.—Risk Factors" in the Company's annual report on Form 20-F, filed with the Securities and Exchange Commission ("SEC") on April 24, 2023, and the risk factors included in our other SEC filings for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.   

    Condensed Consolidated Interim Statement of Loss and Comprehensive Loss

    (Unaudited - expressed in thousands of Canadian dollars, except per share amounts)





    Three months ended

    September 30





    Nine months ended

    September 30







    2023





    2022





    2023





    2022



    Gross revenue





    249,796







    235,144







    696,118







    482,828



    Excise taxes





    12,201







    4,644







    35,562







    11,036



    Net revenue





    237,595







    230,500







    660,556







    471,792



    Cost of sales





    180,375







    179,093







    503,444







    367,710



    Inventory impairment and obsolescence





    9,126







    (2,307)







    22,594







    3,545



    Gross margin before fair value adjustments





    48,094







    53,714







    134,518







    100,537



    Change in fair value of biological assets





    (1,819)







    (1,899)







    (6,767)







    1,403



    Change in fair value realized through inventory





    2,330







    (1,506)







    5,328







    (5,133)



    Gross margin





    48,605







    50,309







    133,079







    96,807





































    Interest and fee revenue





    3,445







    4,312







    11,077







    10,750



    Investment loss





    (29)







    (5,513)







    (9,218)







    (58,296)



    Share of profit (loss) of equity-accounted investees





    6,581







    9,176







    15,161







    (24,711)





































    General and administrative





    48,235







    45,014







    149,535







    95,989



    Sales and marketing





    3,271







    1,935







    10,761







    6,178



    Research and development





    57







    1,503







    217







    1,988



    Depreciation and amortization





    15,545







    9,783







    45,456







    19,322



    Share-based compensation





    5,373







    2,069







    11,475







    6,711



    Restructuring costs





    708







    —







    6,286







    (882)



    Asset impairment





    1,783







    86,522







    4,248







    88,372



    Loss from operations





    (16,370)







    (88,542)







    (77,879)







    (193,128)





































    Transaction costs





    (226)







    (417)







    (2,439)







    1,040



    Finance costs, net





    (2,142)







    (8,409)







    (9,773)







    (34,853)



    Change in estimate of fair value of derivative warrants                         





    (2,840)







    (8,500)







    4,202







    6,856



    Foreign exchange gain (loss)





    (235)







    91







    (429)







    102



    Gain (loss) on disposition of assets





    (14)







    6







    (275)







    408



    Loss before income tax





    (21,827)







    (105,771)







    (86,593)







    (219,575)



    Income tax recovery





    —







    6,927







    —







    8,718



    Net loss from continuing operations





    (21,827)







    (98,844)







    (86,593)







    (210,857)



    Net loss from discontinued operations





    —







    —







    (4,535)







    —



    Net loss





    (21,827)







    (98,844)







    (91,128)







    (210,857)





































    Equity-accounted investees - share of other comprehensive 

    income (loss)





    11,124







    23,194







    (882)







    29,188



    Comprehensive loss





    (10,703)







    (75,650)







    (92,010)







    (181,669)





































    Net loss from continuing operations attributable to:               

































    Owners of the Company





    (21,784)







    (98,108)







    (85,337)







    (209,313)



    Non-controlling interest





    (43)







    (736)







    (1,256)







    (1,544)









    (21,827)







    (98,844)







    (86,593)







    (210,857)



    Net loss attributable to:

































    Owners of the Company





    (21,784)







    (98,108)







    (89,872)







    (209,313)



    Non-controlling interest





    (43)







    (736)







    (1,256)







    (1,544)









    (21,827)







    (98,844)







    (91,128)







    (210,857)



    Comprehensive loss attributable to:

































    Owners of the Company





    (10,660)







    (74,914)







    (90,754)







    (180,125)



    Non-controlling interest





    (43)







    (736)







    (1,256)







    (1,544)



    Condensed Consolidated Interim Statement of Financial Position

    (Unaudited - expressed in thousands of Canadian dollars)

    As at

    September 30, 2023



    December 31, 2022

















    Assets













    Current assets













    Cash and cash equivalents



    201,983





    279,586



    Restricted cash



    19,661





    19,338



    Marketable securities



    265





    21,926



    Accounts receivable



    25,505





    22,636



    Biological assets



    562





    3,477



    Inventory



    142,550





    127,782



    Prepaid expenses and deposits



    17,814





    10,110



    Investments



    3,400





    6,552



    Assets held for sale



    8,391





    6,375



    Net investment in subleases



    3,603





    3,701







    423,734





    501,483



    Non-current assets













    Long-term deposits



    9,720





    8,584



    Right of use assets



    133,792





    134,154



    Property, plant and equipment



    176,144





    143,409



    Net investment in subleases



    18,262





    19,618



    Intangible assets



    73,776





    74,885



    Investments



    29,058





    90,702



    Equity-accounted investees



    550,523





    519,255



    Goodwill



    148,282





    67,260



    Total assets



    1,563,291





    1,559,350

















    Liabilities













    Current liabilities













    Accounts payable and accrued liabilities



    57,230





    48,153



    Lease liabilities



    33,809





    30,206



    Derivative warrants



    6,800





    11,002







    97,839





    89,361



    Non-current liabilities













    Lease liabilities



    137,201





    139,625



    Other liabilities



    6,860





    2,709



    Total liabilities



    241,900





    231,695

















    Shareholders' equity













    Share capital



    2,366,775





    2,292,810



    Warrants



    2,260





    2,260



    Contributed surplus



    76,912





    68,961



    Contingent consideration



    2,279





    2,279



    Accumulated deficit



    (1,178,063)





    (1,091,999)



    Accumulated other comprehensive income



    31,306





    32,188



    Total shareholders' equity



    1,301,469





    1,306,499



    Non-controlling interest



    19,922





    21,156



    Total liabilities and shareholders' equity



    1,563,291





    1,559,350



    Condensed Consolidated Interim Statement of Cash Flows

    (Unaudited - expressed in thousands of Canadian dollars)





    Three months ended

    September 30





    Nine months ended

    September 30







    2023





    2022





    2023





    2022



    Cash provided by (used in):

































    Operating activities

































    Net loss for the period





    (21,827)







    (98,844)







    (91,128)







    (210,857)



    Adjustments for:

































    Income tax recovery





    —







    (6,927)







    —







    (8,718)



    Interest and fee revenue





    (3,445)







    (4,312)







    (11,077)







    (10,750)



    Change in fair value of biological assets





    1,819







    1,899







    6,767







    (1,403)



    Share-based compensation





    5,373







    2,069







    11,475







    6,711



    Depreciation and amortization





    16,602







    11,294







    49,535







    24,271



    Loss (gain) on disposition of assets





    14







    (6)







    275







    (408)



    Inventory obsolescence





    9,126







    (2,307)







    22,594







    3,545



    Finance costs





    2,142







    8,409







    9,773







    34,853



    Change in estimate of fair value of derivative warrants   





    2,840







    8,500







    (4,202)







    (6,856)



    Unrealized foreign exchange loss (gain)





    68







    (75)







    44







    (40)



    Asset impairment





    1,783







    86,522







    4,248







    88,372



    Share of (profit) loss of equity-accounted investees





    (6,581)







    (9,176)







    (15,161)







    24,711



    Realized loss on settlement of marketable securities





    46,082







    —







    138,874







    —



    Unrealized loss on marketable securities





    (46,053)







    5,513







    (129,656)







    58,685



    Additions to marketable securities





    —







    —







    —







    (3,500)



    Proceeds from settlement of marketable securities





    3,241







    —







    6,704







    —



    Income distributions from equity-accounted investees





    —







    976







    —







    1,661



    Interest received





    3,325







    3,874







    10,245







    9,673



    Change in non-cash working capital





    13,033







    1,163







    (43,722)







    (45,271)



    Net cash provided by (used in) operating activities from continuing

    operations





    27,542







    8,572







    (34,412)







    (35,321)



    Net cash provided by operating activities from discontinued

    operations





    —







    —







    4,314







    —



    Net cash provided by (used in) operating activities





    27,542







    8,572







    (30,098)







    (35,321)



    Investing activities

































    Additions to property, plant and equipment





    (3,042)







    (2,119)







    (5,683)







    (6,654)



    Additions to intangible assets





    (32)







    —







    (88)







    (55)



    Additions to investments





    195







    (60,676)







    (507)







    (74,770)



    Additions to equity-accounted investees





    —







    (8,072)







    (16,989)







    (102,272)



    Proceeds from disposal of property, plant and equipment





    1,150







    3







    1,287







    4,003



    Acquisitions, net of cash acquired





    —







    —







    3,695







    (31,149)



    Change in non-cash working capital





    730







    (754)







    1,857







    (495)



    Net cash used in investing activities from continuing operations





    (999)







    (71,618)







    (16,428)







    (211,392)



    Net cash used in investing activities from discontinued operations





    —







    —







    —







    —



    Net cash used in investing activities





    (999)







    (71,618)







    (16,428)







    (211,392)



    Financing activities

































    Change in restricted cash





    (205)







    70







    (323)







    7,677



    Payments on lease liabilities, net





    (9,793)







    (9,127)







    (29,400)







    (18,751)



    Repurchase of common shares, net of costs





    —







    (4,096)







    (1,536)







    (6,149)



    Repayment of long-term debt





    —







    —







    —







    (10,000)



    Change in non-cash working capital





    (17)







    4,996







    182







    7,112



    Net cash used in financing activities from continuing operations





    (10,015)







    (8,157)







    (31,077)







    (20,111)



    Net cash used in financing activities from discontinued operations       





    —







    —







    —







    —



    Net cash used in financing activities





    (10,015)







    (8,157)







    (31,077)







    (20,111)



    Change in cash and cash equivalents





    16,528







    (71,203)







    (77,603)







    (266,824)



    Cash and cash equivalents, beginning of period





    185,455







    362,630







    279,586







    558,251



    Cash and cash equivalents, end of period





    201,983







    291,427







    201,983







    291,427



    SPECIFIED FINANCIAL MEASURES  

    Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures provided by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team. 

    ADJUSTED EBITDA

    Adjusted EBITDA is a non-IFRS measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company's operating results in a manner similar to its management team. Adjusted EBITDA is defined as net income (loss) from continuing operations before finance costs, change in estimate of fair value of derivative warrants, depreciation and amortization, income tax recovery and excluding change in fair value of biological assets, change in fair value realized through inventory, unrealized foreign exchange gains or losses, unrealized gains or losses on marketable securities, realized gains or losses on marketable securities, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment, cost of sales non-cash component, inventory impairment (recovery) and obsolescence, restructuring costs and transaction costs.. The Company presents both consolidated or total Adjusted EBITDA and Adjusted EBITDA by operating segment.

    OPERATING SEGMENTS





























    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Three months ended September 30, 2023





































    Net earnings (loss)



    6,449





    2,753





    (13,774)





    9,834





    (27,089)





    (21,827)



    Adjustments





































    Finance costs



    1,652





    679





    (241)





    52





    —





    2,142



    Change in estimate of fair value of derivative

    warrants



    —





    —





    —





    —





    2,840





    2,840



    Depreciation and amortization



    9,436





    4,340





    954





    —





    815





    15,545



    Change in fair value of biological assets



    —





    —





    1,819





    —





    —





    1,819



    Change in fair value realized through inventory



    —





    —





    (2,330)





    —





    —





    (2,330)



    Unrealized foreign exchange (gain) loss



    —





    —





    68





    —





    —





    68



    Unrealized (gain) loss on marketable securities     



    —





    —





    114





    (46,167)





    —





    (46,053)



    Realized loss on marketable securities



    —





    —





    —





    46,082





    —





    46,082



    Share-based compensation



    —





    2





    —





    —





    5,371





    5,373



    Asset impairment



    1,640





    108





    35





    —





    —





    1,783



    Loss (gain) on disposition of PP&E



    (21)





    49





    (14)





    —





    —





    14



    Cost of sales non-cash component (1)



    —





    —





    601





    —





    —





    601



    Inventory impairment (recovery) and

    obsolescence



    —





    —





    9,126





    —





    —





    9,126



    Restructuring costs



    —





    —





    (323)





    —





    1,031





    708



    Transaction costs



    —





    —





    —





    —





    226





    226



    Adjusted EBITDA



    19,156





    7,931





    (3,965)





    9,801





    (16,806)





    16,117



    (1) Cost of sales non-cash component is comprised of depreciation expense







    OPERATING SEGMENTS





























    ($000s)

    Liquor

    Retail



    Cannabis

    Retail



    Cannabis

    Operations



    Investments



    Corporate



    Total



    Three months ended September 30, 2022





































    Net earnings (loss)



    10,736





    (84,848)





    (5,686)





    10,179





    (29,225)





    (98,844)



    Adjustments





































    Finance costs



    2,570





    1,142





    13





    4,684





    —





    8,409



    Change in estimate of fair value of derivative

    warrants



    —





    —





    —





    —





    8,500





    8,500



    Depreciation and amortization



    407





    2,076





    —





    —





    7,300





    9,783



    Income tax recovery



    —





    —





    —





    (6,927)





    —





    (6,927)



    Change in fair value of biological assets



    —





    —





    1,899





    —





    —





    1,899



    Change in fair value realized through inventory



    —





    —





    1,506





    —





    —





    1,506



    Unrealized foreign exchange (gain) loss



    (2)





    —





    (73)





    —





    —





    (75)



    Unrealized (gain) loss on marketable securities     



    —





    —





    —





    5,513





    —





    5,513



    Share-based compensation



    —





    105





    —





    —





    1,964





    2,069



    Asset impairment



    —





    84,366





    2,156





    —





    —





    86,522



    Loss (gain) on disposition of PP&E



    (4)





    (2)





    —





    —





    —





    (6)



    Cost of sales non-cash component (1)



    —





    —





    1,861





    —





    —





    1,861



    Inventory impairment (recovery) and

    obsolescence



    —





    —





    (2,307)





    —





    —





    (2,307)



    Restructuring costs



    —





    —





    —





    —





    —





    —



    Transaction costs



    —





    —





    —





    —





    417





    417



    Adjusted EBITDA



    13,707





    2,839





    (631)





    13,449





    (11,044)





    18,320



    (1) Cost of sales non-cash component is comprised of depreciation expense



    FREE CASH FLOW

    Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance. Free cash flow provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company's ability to generate positive cash flows as it removes cash used for non-operational items. Free cash flow is defined as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), net cash used for acquisitions plus cash provided by dispositions (if any).





    Three months ended

    September 30



    ($000s)





    2023



    2022



    Change in cash and cash equivalents                                                                                                             







    16,528





    (71,203)



    Adjustments

















    Repurchase of common shares







    —





    4,096



    Free cash flow







    16,528





    (67,107)



    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sndl-reports-third-quarter-2023-financial-and-operational-results-and-achieves-positive-net-cash-from-operating-activities-and-free-cash-flow-301985520.html

    SOURCE SNDL Inc.

    Get the next $SNDL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDL

    DatePrice TargetRatingAnalyst
    9/3/2025$5.00Buy
    Alliance Global Partners
    7/17/2024Speculative Buy
    Canaccord Genuity
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $SNDL
    SEC Filings

    View All

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    3/12/26 6:55:05 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    2/19/26 4:40:03 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    1/7/26 4:32:18 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

    EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue for the fourth quarter of 2025 was $252.

    3/12/26 6:55:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on SNDL Inc. with a new price target

    Alliance Global Partners initiated coverage of SNDL Inc. with a rating of Buy and set a new price target of $5.00

    9/3/25 7:54:28 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity resumed coverage on SNDL Inc.

    Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

    7/17/24 12:19:57 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

    8/16/22 7:59:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Leadership Updates

    Live Leadership Updates

    View All

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Appoints New Chief Information Officer and New President, Liquor Division

    CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

    11/21/24 6:02:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2024 Annual General Meeting Results

    CALGARY, AB, July 30, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual General Meeting (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at six (6); (ii) electing each of Gregory Mills, Zachary George, Lori Ell, Frank Krasovec, Bryan Pinney and Gregory Turnbull as directors of the Company for the ensuing year; and (iii) re-appointing Marcum LLP as the auditors of the Company for the ensu

    7/30/24 5:45:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Financials

    Live finance-specific insights

    View All

    SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

    EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue for the fourth quarter of 2025 was $252.

    3/12/26 6:55:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    1/31/24 4:48:48 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Subject)

    2/14/23 5:28:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    2/13/23 4:06:09 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care